跳到正文
BioPharm International·· 19 天前AI 评分50

爱荷华大学在AAPS PharmSci 360 2026展示:偶联改变曲妥珠单抗在溶液与界面中的行为,建议DLS联合QCM-D

How Conjugation Changes Antibody Behavior in Solution and at Interfaces

AI 导读

爱荷华大学博士生Siddhanth Hejmady在AAPS PharmSci 360 2026报告,将曲妥珠单抗与两种ADC及一种放射免疫偶联物对比,发现偶联不仅改变治疗功能,也改变抗体表面性质。两种技术结果并不总是一致:曲妥珠单抗德鲁替康在溶液中kD较高,但界面可逆自缔合更强;放射免疫偶联物形成更牢固的不可逆吸附层。他建议开发性团队将DLS与QCM-D联用,以在早期识别相关风险。

正文 · 原文

News|Videos|November 3, 2026

At AAPS PharmSci 360 2026, University of Iowa PhD candidate Siddhanth Hejmady explains how adding a payload or radiolabel to trastuzumab changes its behavior in bulk solution and at interfaces, and why developability teams should pair DLS with QCM-D.

Attaching a cytotoxic payload or a radiolabel to an antibody is meant to change what the molecule does in the body. It can also change how the molecule behaves in solution and at the surfaces it contacts before it ever reaches a patient.

In this video interview for BioPharm International®’s AAPS PharmSci 360 2026 coverage, Siddhanth Hejmady discussed the poster he presented at the conference. The poster compared trastuzumab with two antibody-drug conjugates (ADCs) and one radioimmunoconjugate (RIC).

Hejmady, a fifth-year PhD candidate at the University of Iowa, said the team chose trastuzumab as the parent scaffold because it is stable, well characterized, and relevant to the pharmaceutical and biotechnology industry. The goal was to see how adding a small molecule to a large molecule changes its behavior in bulk solution and at interfaces.

“Conjugation does not just change the therapeutic function of a large molecule; it changes the antibody surface properties as well.” – Siddhanth Hejmady, PhD candidate, University of Iowa

To measure both, the team paired two techniques. Dynamic light scattering (DLS) tracks concentration-dependent diffusion, which indicates protein-protein interactions in bulk solution, Hejmady explained. Quartz crystal microbalance with dissipation monitoring (QCM-D) measures adsorption and self-association at a sensor surface. Its frequency output reflects the mass of protein on the sensor, and its dissipation output reflects the viscoelasticity, or softness, of the adsorbed layer.

The approach builds on earlier work by Hejmady and University of Iowa colleagues in Molecular Pharmaceutics. Across eight monoclonal antibodies, that study found that the loosely interacting layer detected by QCM-D showed a strong rank-order correlation with the diffusion interaction parameter (kD) measured by DLS.

QCM-D also separates two populations, he said. The irreversibly bound layer, left on the sensor after a buffer wash, reflects protein-surface interactions. The reversibly bound layer, loosely associated with that first layer, serves as a surrogate for self-association.

“These two metrics, on the whole, give an idea for different formulators and drug developers in terms of making different and more informed decisions from a formulation screening point of view, from a point of view of primary packaging contact materials as well,” Hejmady said.

“Those are the two major techniques that we use in our study, which helped us look into the molecules from a complementary and orthogonal type of characterization.” – Siddhanth Hejmady, PhD candidate, College of Pharmacy, University of Iowa

What stood out across the antibody modalities?

The two techniques did not always point in the same direction. Trastuzumab deruxtecan had a relatively higher kD, indicating more repulsive protein-protein interactions in bulk solution. Even so, it showed higher reversible self-association at the interface, unlike the study’s other ADC, trastuzumab emtansine. The RIC formed a stronger irreversibly bound layer, which Hejmady described as “a more persistent” form of surface retention.

Interfacial behavior has consequences for stability. Antibody interactions with interfaces can cause denaturation and subvisible particle formation, according to a review published in Molecules.

As pipelines move toward more complex modalities, Hejmady said developability deserves the same weight as therapeutic function. “Because at the end of the day, any molecule or any conjugate has to be manufacturable, it has to be stable, it has to be deliverable,” he said.

He argued that developers need a broader toolkit that pairs traditional tools such as DLS with newer ones such as QCM-D, because each shows the molecule in a different context. That combination, he said, “would help us identify liabilities early on.”

AAPS PharmSci 360 2026 took place October 25–28 in New Orleans. Explore more conference coverage here.

About the Speaker

Siddhanth Hejmady, fifth-year PhD candidate, University of Iowa

Hejmady studies biologic drug product development, including formulation, analysis, and characterization. He has worked with monoclonal antibodies, ADCs, radioimmunoconjugates, bispecifics, and peptides. He earned his bachelor’s and master’s degrees in pharmacy and pharmaceutics in India and worked at Cipla. He has also worked in formulation development and sterile drug product manufacturing at University of Iowa Pharmaceuticals, a CDMO associated with the College of Pharmacy. In 2024, he interned in parenteral manufacturing sciences and technology at Bristol Myers Squibb.

Related to this article

18-Month Room-Temperature Data Support Hyaluronidase-Free Antibody Suspensions, Says Nanoform’s Chris Worrall

October 30th, 2026

In an interview for BioPharm International’s AAPS PharmSci 360 2026 coverage, Nanoform’s Chris Worrall shares 18-month stability data for a 440 mg/mL trastuzumab suspension and explains how ultra-high-concentration formulations could shorten administration and support at-home injection.

Read more

Antibody Manufacturing Costs Have Fallen From $35 to About $12 per Gram, Says IIT Delhi’s Anurag Rathore

October 29th, 2026

In the final part of a three-part interview, Anurag Rathore, PhD, professor of chemical engineering at IIT Delhi, explains how his team has cut monoclonal antibody costs toward $10 per gram and why process intensification will spread one unit operation at a time.

Read more

Non-Aqueous Suspensions Could Push Antibody Concentrations Above 400 mg/mL, Says Nanoform’s Chris Worrall

October 29th, 2026

As part of BioPharm International’s AAPS PharmSci 360 2026 coverage, Nanoform’s Chris Worrall explains why stability and viscosity have kept antibody formulations below 200 mg/mL, and how a low-temperature particle engineering process and non-aqueous suspensions could support ultra-high concentrations.

Read more

$10-per-Gram Antibodies Could Compete With Vaccines Against Infectious Disease, Says IIT Delhi’s Anurag Rathore

October 28th, 2026

Anurag Rathore, PhD, professor of chemical engineering at IIT Delhi, explains how his team cuts monoclonal antibody costs without cutting purification steps, and why the $10-per-gram target could make antibodies viable for infectious disease and global access.

Read more

Overhead view of a busy conference exhibit hall, with attendees wearing lanyards walking down an aisle between rows of white-walled booths with tables, displays, and lab equipment. | Image Credit: © AAPS/Courtesy of Contract Pharma

November 2nd, 2026

AAPS PharmSci 360 2026 in New Orleans centered on auditable AI, modeling-guided formulation, oral peptide delivery, high-concentration antibody suspensions, and the push toward $10-per-gram monoclonal antibodies.

Read more

AAPS 2026 PharmSci 360 Video Recap: AI Transparency, Oral Peptides, and New Models

October 30th, 2026

This year’s AAPS PharmSci 360 highlighted AI transparency, computer modeling in formulation, oral peptide delivery, and new business models.

Read more

Why Highly Potent Peptides Can Succeed with Low Oral Bioavailability

October 28th, 2026

Catalent Pharma Solutions's Dr Karunakar Sukuru explains how peptide potency, dose, and patient needs guide the choice between softgel and sublingual dosage forms.

Read more

White powder in a round glass Petri dish on a blue background, with a wooden spatula resting in the dish and holding a small mound of the powder. | Image Credit: © AB-7272 - stock.adobe.com

October 27th, 2026

At AAPS PharmSci 360, Thermo Fisher Scientific scientists described how predictive modeling guides technology selection for poorly soluble drugs, and outlined plans to bring solvent-free KinetiSol technology to commercial scale in 2027.

Read more

来源:BioPharm International · biopharminternational.com